Exelixis Inc

EXEL

43.900USD

+1.530+3.61%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Exelixis Inc's Score

Industry at a Glance

Industry Ranking

16 / 392

Overall Ranking

105 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Exelixis Inc Highlights

StrengthsRisks

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 34.61% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.17B.

Undervalued

The company’s latest PE is 17.85, at a low 3-year percentile range.

Held by Ken Fisher

Star Investor Ken Fisher holds 46.81K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.11.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

46.000

Target Price

+8.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Exelixis Inc is 7.27, ranking 131 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 597.75M, representing a year-over-year increase of 10.79%, while its net profit experienced a year-over-year increase of 64.09%.

Score

Industry at a Glance

Previous score

7.27

Change

0



Financials

7.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.25

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.25

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.31

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Exelixis Inc is 7.03, ranking 184 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 17.85, which is 373.73% below the recent high of 84.56 and 14.86% above the recent low of 15.20.

Score

Industry at a Glance

Previous score

7.03

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 16/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Exelixis Inc is 7.24, ranking 306 out of 392 in the Biotechnology & Medical Research industry. The average price target is 45.50, with a high of 60.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

7.24

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Exelixis Inc is 9.06, ranking 41 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 46.27 and the support level at 41.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.24

Change

1.82

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Exelixis Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 98.50%, representing a quarter-over-quarter decrease of 1.36%. The largest institutional shareholder is The Vanguard, holding a total of 25.43M shares, representing 9.48% of shares outstanding, with 9.60% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

26.00M

-5.14%

BlackRock Institutional Trust Company, N.A.

25.01M

-1.68%

Farallon Capital Management, L.L.C.

19.50M

+21.61%

Renaissance Technologies LLC

Star Investors

15.46M

-2.28%

State Street Investment Management (US)

11.11M

-2.37%

AQR Capital Management, LLC

9.18M

+20.71%

Fuller & Thaler Asset Management Inc.

8.32M

-5.18%

LSV Asset Management

7.77M

-0.66%

Geode Capital Management, L.L.C.

7.67M

+3.03%

Arrowstreet Capital, Limited Partnership

5.27M

+0.10%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Exelixis Inc is 7.37, ranking 13 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Exelixis Inc

EXEL

7.87 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment